{
  "PMC": "9817464",
  "DOI": "10.1007/s12257-022-0107-8",
  "PMID": "36627930",
  "PMCID": "PMC9817464",
  "title": "Virus-like Particles as Antiviral Vaccine: Mechanism, Design, and Application.",
  "year": 2023,
  "source_url": "https://europepmc.org/article/PMC/PMC9817464",
  "source": "MED",
  "abstract_text": "Virus-like particles (VLPs) are viral structural protein that are noninfectious as they do not contain viral genetic materials. They are safe and effective immune stimulators and play important roles in vaccine development because of their intrinsic immunogenicity to induce cellular and humoral immune responses. In the design of antiviral vaccine, VLPs based vaccines are appealing multifunctional candidates with the advantages such as self-assembling nanoscaled structures, repetitive surface epitopes, ease of genetic and chemical modifications, versatility as antigen presenting platforms, intrinsic immunogenicity, higher safety profile in comparison with live-attenuated vaccines and inactivated vaccines. In this review, we discuss the mechanism of VLPs vaccine inducing cellular and humoral immune responses. We outline the impact of size, shape, surface charge, antigen presentation, genetic and chemical modification, and expression systems when constructing effective VLPs based vaccines. Recent applications of antiviral VLPs vaccines and their clinical trials are summarized.",
  "full_text": "pmc Biotechnol Bioprocess Eng Biotechnol Bioprocess Eng Biotechnology and Bioprocess Engineering 1226-8372 1976-3816 The Korean Society for Biotechnology and Bioengineering Seoul 9817464 36627930 107 10.1007/s12257-022-0107-8 Review Paper Virus-like Particles as Antiviral Vaccine: Mechanism, Design, and Application Zhang Lei Xu Wen Ma Xi Sun XiaoJing Fan JinBo Wang Yang yang.wang@xiyi.edu.cn grid.508540.c 0000 0004 4914 235X Xi’an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Department of Basic Medicine, Xi’an Medical University, Xi’an, 710021, Shaanxi China 6 1 2023 2023 28 1 1 16 1 4 2022 17 5 2022 18 5 2022 © The Korean Society for Biotechnology and Bioengineering and Springer 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. Virus-like particles (VLPs) are viral structural protein that are noninfectious as they do not contain viral genetic materials. They are safe and effective immune stimulators and play important roles in vaccine development because of their intrinsic immunogenicity to induce cellular and humoral immune responses. In the design of antiviral vaccine, VLPs based vaccines are appealing multifunctional candidates with the advantages such as self-assembling nanoscaled structures, repetitive surface epitopes, ease of genetic and chemical modifications, versatility as antigen presenting platforms, intrinsic immunogenicity, higher safety profile in comparison with live-attenuated vaccines and inactivated vaccines. In this review, we discuss the mechanism of VLPs vaccine inducing cellular and humoral immune responses. We outline the impact of size, shape, surface charge, antigen presentation, genetic and chemical modification, and expression systems when constructing effective VLPs based vaccines. Recent applications of antiviral VLPs vaccines and their clinical trials are summarized. Keywords virus-like particles viral infection immune response antiviral vaccine antigen presentation issue-copyright-statement © The Korean Society for Biotechnology and Bioengineering 2023 Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements This research was funded by National Natural Science Foundation of China, grant number 32070069 (Y.W.); Shaanxi Provincial Department of Science and Technology, grant number 2021JM-506 (L.Z.) and 2021JQ-781 (X.M.); Shaanxi Provincial Department of Education, grant number 20JS140 (L.Z.); Xi’an Medical University, grant number 2020DOC20 (L.Z.). Author’s Contributions Conceptualization, L.Z. and Y.W.; investigation, L.Z., X.M., JB.F., and XJ.S.; writing-original draft preparation, L.Z. and Y.W.; writing-review and editing, W.X. and Y.W.; final approval of the version to be submitted, Y.W. All authors have read and agreed to the published version of the manuscript. Ethical Statements The authors declare no conflict of interest. Neither ethical approval nor informed consent was required for this study. References 1. Mohsen M O Zha L Cabral-Miranda G Bachmann M F Major findings and recent advances in virus-like particle (VLP)-based vaccines Semin. Immunol. 2017 34 123 132 10.1016/j.smim.2017.08.014 28887001 2. Shoeb E Hefferon K Future of cancer immunotherapy using plant virus-based nanoparticles Future Sci. OA 2019 5 FSO401 10.2144/fsoa-2019-0001 31428448 3. Zeltins A Construction and characterization of viruslike particles: a review Mol. Biotechnol. 2013 53 92 107 10.1007/s12033-012-9598-4 23001867 4. Bárcena J Blanco E Design of novel vaccines based on virus-like particles or chimeric virions Subcell. Biochem. 2013 68 631 665 10.1007/978-94-007-6552-8_21 23737067 5. Kitazawa M Anantharam V Kanthasamy A Kanthasamy A G Dieldrin promotes proteolytic cleavage of poly(ADP-ribose) polymerase and apoptosis in dopaminergic cells: protective effect of mitochondrial anti-apoptotic protein Bcl-2 Neurotoxicology 2004 25 589 598 10.1016/j.neuro.2003.09.014 15183012 6. Donaldson B Lateef Z Walker G F Young S L Ward V K Virus-like particle vaccines: immunology and formulation for clinical translation Expert Rev. Vaccines 2018 17 833 849 10.1080/14760584.2018.1516552 30173619 7. Sieczkarski S B Whittaker G R Dissecting virus entry via endocytosis J. Gen. Virol. 2002 83 1535 1545 10.1099/0022-1317-83-7-1535 12075072 8. Grönwall C Sjöberg A Ramström M Höiden-Guthenberg I Hober S Jonasson P Ståhl S Affibody-mediated transferrin depletion for proteomics applications Biotechnol. J. 2007 2 1389 1398 10.1002/biot.200700053 17639529 9. Zepeda-Cervantes J Ramírez-Jarquín J O Vaca L Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs Front. Immunol. 2020 11 1100 10.3389/fimmu.2020.01100 32582186 10. Mohsen M O Gomes A C Vogel M Bachmann M F Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system Vaccines (Basel) 2018 6 37 10.3390/vaccines6030037 30004398 11. Peacey M Wilson S Perret R Ronchese F Ward V K Young V Young S L Baird M A Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response Vaccine 2008 26 5334 5337 10.1016/j.vaccine.2008.07.074 18706958 12. Schwarz K Meijerink E Speiser D E Tissot A C Cielens I Renhof R Dishlers A Pumpens P Bachmann M F Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles Eur. J. Immunol. 2005 35 816 821 10.1002/eji.200425755 15724244 13. Andersson A C Schwerdtfeger M Holst P J Virus-like-vaccines against HIV Vaccines (Basel) 2018 6 10 10.3390/vaccines6010010 29439476 14. Valerdi K M Hage A van Tol S Rajsbaum R Giraldo M I The role of the host ubiquitin system in promoting replication of emergent viruses Viruses 2021 13 369 10.3390/v13030369 33652634 15. van Gent M Sparrer K M J Gack M U TRIM proteins and their roles in antiviral host defenses Annu. Rev. Virol. 2018 5 385 405 10.1146/annurev-virology-092917-043323 29949725 16. Foss S Bottermann M Jonsson A Sandlie I James L C Andersen J T TRIM21-from intracellular immunity to therapy Front. Immunol. 2019 10 2049 10.3389/fimmu.2019.02049 31555278 17. Davis M E Gack M U Ubiquitination in the antiviral immune response Virology 2015 479–480 52 65 10.1016/j.virol.2015.02.033 25753787 18. Jimenez-Moyano E Ruiz A Kløverpris H N Rodriguez-Plata M T Peña R Blondeau C Selwood D L Izquierdo-Useros N Moris A Clotet B Goulder P Towers G J Prado J G Nonhuman TRIM5 variants enhance recognition of HIV-1-infected cells by CD8 + T cells J. Virol. 2016 90 8552 8562 10.1128/JVI.00819-16 27440884 19. Chackerian B Durfee M R Schiller J T Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model J. Immunol. 2008 180 5816 5825 10.4049/jimmunol.180.9.5816 18424700 20. Bessa J Zabel F Link A Jegerlehner A Hinton H J Schmitz N Bauer M Kündig T M Saudan P Bachmann M F Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses Proc. Natl. Acad. Sci. U. S. A. 2012 109 20566 20571 10.1073/pnas.1206970109 23169669 21. Yang R Murillo F M Delannoy M J Blosser R L Yutzy W H Uematsu S Takeda K Akira S Viscidi R P Roden R B B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88 J. Immunol. 2005 174 7912 7919 10.4049/jimmunol.174.12.7912 15944297 22. Peek L J Middaugh C R Berkland C Nanotechnology in vaccine delivery Adv. Drug Deliv. Rev. 2008 60 915 928 10.1016/j.addr.2007.05.017 18325628 23. Grgacic E V Anderson D A Virus-like particles: passport to immune recognition Methods 2006 40 60 65 10.1016/j.ymeth.2006.07.018 16997714 24. Manolova V Flace A Bauer M Schwarz K Saudan P Bachmann M F Nanoparticles target distinct dendritic cell populations according to their size Eur. J. Immunol. 2008 38 1404 1413 10.1002/eji.200737984 18389478 25. Nygren P A Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold FEBS J. 2008 275 2668 2676 10.1111/j.1742-4658.2008.06438.x 18435759 26. Larsson M Beignon A S Bhardwaj N DC-virus interplay: a double edged sword Semin. Immunol. 2004 16 147 161 10.1016/j.smim.2004.02.002 15130499 27. Morón G Dadaglio G Leclerc C New tools for antigen delivery to the MHC class I pathway Trends Immunol. 2004 25 92 97 10.1016/j.it.2003.11.008 15102368 28. Shahrivarkevishahi A Hagge L M Brohlin O R Kumari S Ehrman R Benjamin C Gassensmith J J Mater. Today Chem. 2022 24 100808 10.1016/j.mtchem.2022.100808 29. Boland B Campbell V beta-Amyloid (1-40)-induced apoptosis of cultured cortical neurones involves calpain-mediated cleavage of poly-ADP-ribose polymerase Neurobiol. Aging 2003 24 179 186 10.1016/S0197-4580(02)00060-X 12493564 30. Vaculová A Hofmanova J Soucek K Kovariková M Kozubík A Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells Anticancer Res. 2002 22 1635 1639 12168847 31. Yang Y Zhao S Song J Caspase-dependent apoptosis and -independent poly(ADP-ribose) polymerase cleavage induced by transforming growth factor beta1 Int. J. Biochem. Cell Biol. 2004 36 223 234 10.1016/S1357-2725(03)00215-2 14643888 32. Ching J C Jones N L Ceponis P J Karmali M A Sherman P M Escherichia coli shiga-like toxins induce apoptosis and cleavage of poly(ADP-ribose) polymerase via in vitro activation of caspases Infect. Immun. 2002 70 4669 4677 10.1128/IAI.70.8.4669-4677.2002 12117981 33. D’Amours D Sallmann F R Dixit V M Poirier G G Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis J. Cell Sci. 2001 114 3771 3778 10.1242/jcs.114.20.3771 11707529 34. Liu W Chen Y H High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins Eur. J. Immunol. 2005 35 505 514 10.1002/eji.200425749 15627976 35. Plummer E M Manchester M Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2011 3 174 196 10.1002/wnan.119 20872839 36. Rueda P Hurtado A del Barrio M Martínez-Torrecuadrada J L Kamstrup S Leclerc C Casal J I Minor displacements in the insertion site provoke major differences in the induction of antibody responses by chimeric parvovirus-like particles Virology 1999 263 89 99 10.1006/viro.1999.9911 10544085 37. Christoffer C Bharadwaj V Luu R Kihara D LZerD protein-protein docking webserver enhanced with de novo structure prediction Front. Mol. Biosci. 2021 8 724947 10.3389/fmolb.2021.724947 34466411 38. Suh D Lee J W Choi S Lee Y Recent applications of deep learning methods on evolution- and contact-based protein structure prediction Int. J. Mol. Sci. 2021 22 6032 10.3390/ijms22116032 34199677 39. Leman J K Weitzner B D Lewis S M Adolf-Bryfogle J Alam N Alford R F Aprahamian M Baker D Barlow K A Barth P Basanta B Bender B J Blacklock K Bonet J Boyken S E Bradley P Bystroff C Conway P Cooper S Correia B E Coventry B Das R De Jong R M DiMaio F Dsilva L Dunbrack R Ford A S Frenz B Fu D Y Geniesse C Goldschmidt L Gowthaman R Gray J J Gront D Guffy S Horowitz S Huang P S Huber T Jacobs T M Jeliazkov J R Johnson D K Kappel K Karanicolas J Khakzad H Khar K R Khare S D Khatib F Khramushin A King I C Kleffner R Koepnick B Kortemme T Kuenze G Kuhlman B Kuroda D Labonte J W Lai J K Lapidoth G Leaver-Fay A Lindert S Linsky T London N Lubin J H Lyskov S Maguire J Malmström L Marcos E Marcu O Marze N A Meiler J Moretti R Mulligan V K Nerli S Norn C Ó’Conchúir S Ollikainen N Ovchinnikov S Pacella M S Pan X Park H Pavlovicz R E Pethe M Pierce B G Pilla K B Raveh B Renfrew P D Burman S S R Rubenstein A Sauer M F Scheck A Schief W Schueler-Furman O Sedan Y Sevy A M Sgourakis N G Shi L Siegel J B Silva D A Smith S Song Y Stein A Szegedy M Teets F D Thyme S B Wang R Y Watkins A Zimmerman L Bonneau R Macromolecular modeling and design in Rosetta: recent methods and frameworks Nat. Methods 2020 17 665 680 10.1038/s41592-020-0848-2 32483333 40. Nord K Nord O Uhlén M Kelley B Ljungqvist C Nygren P A Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A Eur. J. Biochem. 2001 268 4269 4277 10.1046/j.1432-1327.2001.02344.x 11488921 41. Akira S Uematsu S Takeuchi O Pathogen recognition and innate immunity Cell 2006 124 783 801 10.1016/j.cell.2006.02.015 16497588 42. Hemmi H Takeuchi O Kawai T Kaisho T Sato S Sanjo H Matsumoto M Hoshino K Wagner H Takeda K Akira S A Toll-like receptor recognizes bacterial DNA Nature 2000 408 740 745 10.1038/35047123 11130078 43. Utaisincharoen P Kespichayawattana W Anuntagool N Chaisuriya P Pichyangkul S Krieg A M Sirisinha S CpG ODN enhances uptake of bacteria by mouse macrophages Clin. Exp. Immunol. 2003 132 70 75 10.1046/j.1365-2249.2003.02107.x 12653838 44. Hennequin B Turyanska L Ben T Beltrán A M Molina S I Li M Mann S Patanè A Thomas N R Aqueous near-infrared fluorescent composites based on apoferritin-encapsulated PbS quantum dots Adv. Mater. 2008 20 3592 3596 10.1002/adma.200800530 45. Destito G Yeh R Rae C S Finn M G Manchester M Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells Chem. Biol. 2007 14 1152 1162 10.1016/j.chembiol.2007.08.015 17961827 46. Aljabali A A Shukla S Lomonossoff G P Steinmetz N F Evans D J CPMV-DOX delivers Mol. Pharm. 2013 10 3 10 10.1021/mp3002057 22827473 47. Jones M W Strickland R A Schumacher F F Caddick S Baker J R Gibson M I Haddleton D M Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents J. Am. Chem. Soc. 2012 134 1847 1852 10.1021/ja210335f 22188166 48. Chen Z Li N Li S Dharmarwardana M Schlimme A Gassensmith J J Viral chemistry: the chemical functionalization of viral architectures to create new technology Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2016 8 512 534 10.1002/wnan.1379 26663821 49. Chen Z Boyd S D Calvo J S Murray K W Mejia G L Benjamin C E Welch R P Winkler D D Meloni G D’Arcy S Gassensmith J J Fluorescent functionalization across quaternary structure in a virus-like particle Bioconjug. Chem. 2017 28 2277 2283 10.1021/acs.bioconjchem.7b00305 28787574 50. Yin Z Comellas-Aragones M Chowdhury S Bentley P Kaczanowska K Benmohamed L Gildersleeve J C Finn M G Huang X Boosting immunity to small tumor-associated carbohydrates with bacteriophage qβ capsids ACS Chem. Biol. 2013 8 1253 1262 10.1021/cb400060x 23505965 51. Thrane S Janitzek C M Agerbæk M Ditlev S B Resende M Nielsen M A Theander T G Salanti A Sander A F A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA PLoS One 2015 10 e0143071 10.1371/journal.pone.0143071 26599509 52. Jeong H Seong B L Exploiting virus-like particles as innovative vaccines against emerging viral infections J. Microbiol. 2017 55 220 230 10.1007/s12275-017-7058-3 28243941 53. Ding X Liu D Booth G Gao W Lu Y Virus-like particle engineering: from rational design to versatile applications Biotechnol. J. 2018 13 e1700324 10.1002/biot.201700324 29453861 54. Boonyakida J Utomo D I S Soma F N Park E Y Two-step purification of tag-free norovirus-like particles from silkworm larvae ( Bombyx mori ) Protein Expr. Purif. 2022 190 106010 10.1016/j.pep.2021.106010 34737040 55. Wikman M Steffen A C Gunneriusson E Tolmachev V Adams G P Carlsson J Ståhl S Selection and characterization of HER2/neu-binding affibody ligands Protein Eng. Des. Sel. 2004 17 455 462 10.1093/protein/gzh053 15208403 56. Wacker M Linton D Hitchen P G Nita-Lazar M Haslam S M North S J Panico M Morris H R Dell A Wren B W Aebi M N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli Science 2002 298 1790 1793 10.1126/science.298.5599.1790 12459590 57. Nakahira Y Mizuno K Yamashita H Tsuchikura M Takeuchi K Shiina T Kawakami H Mass production of virus-like particles using chloroplast genetic engineering for highly immunogenic oral vaccine against fish disease Front. Plant Sci. 2021 12 717952 10.3389/fpls.2021.717952 34497627 58. Daniell H Rai V Xiao Y Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes Plant Biotechnol. J. 2019 17 1357 1368 10.1111/pbi.13060 30575284 59. Panasiuk M Zimmer K Czarnota A Grzyb K Narajczyk M Peszyñska-Sularz G Żołędowska S Nidzworski D Hovhannisyan L Gromadzka B Immunization with Leishmania tarentolae -derived norovirus virus-like particles elicits high humoral response and stimulates the production of neutralizing antibodies Microb. Cell Fact. 2021 20 186 10.1186/s12934-021-01677-1 34560881 60. Kushnir N Streatfield S J Yusibov V Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development Vaccine 2012 31 58 83 10.1016/j.vaccine.2012.10.083 23142589 61. Chroboczek J Szurgot I Szolajska E Virus-like particles as vaccine Acta Biochim. Pol. 2014 61 531 539 10.18388/abp.2014_1875 25273564 62. Yap I Guan R Chan S H Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein— a preliminary study on immunogenicity Vaccine 1992 10 439 442 10.1016/0264-410X(92)90391-V 1535170 63. Mikaeloff Y Caridade G Suissa S Tardieu M Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood Neurology 2009 72 873 880 10.1212/01.wnl.0000335762.42177.07 18843097 64. Zuckerman J N Zuckerman A J Symington I Du W Williams A Dickson B Young M D UK Hepacare Study Group Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines Hepatology 2001 34 798 802 10.1053/jhep.2001.27564 11584378 65. Pol S Driss F Michel M L Nalpas B Berthelot P Brechot C Specific vaccine therapy in chronic hepatitis B infection Lancet 1994 344 342 10.1016/S0140-6736(94)91384-6 7914291 66. Qawasmi M Samuh M Glebe D Gerlich W H Azzeh M Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood Hum. Vaccin. Immunother. 2015 11 1717 1724 10.1080/21645515.2015.1041687 25996579 67. Macartney K K Chiu C Georgousakis M Brotherton J M Safety of human papillomavirus vaccines: a review Drug Saf. 2013 36 393 412 10.1007/s40264-013-0039-5 23637071 68. Stanley M HPV vaccines: alternative dosage schedules Expert Rev. Vaccines 2019 18 1309 1316 10.1080/14760584.2019.1704261 31847625 69. Wang D Liu X Wei M Qian C Song S Chen J Wang Z Xu Q Yang Y He M Chi X Huang S Li T Kong Z Zheng Q Yu H Wang Y Zhao Q Zhang J Xia N Gu Y Li S Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles Nat. Commun. 2020 11 2841 10.1038/s41467-020-16639-1 32503989 70. Yadav R Zhai L Tumban E Virus-like particle-based L2 vaccines against HPVs: where are we today? Viruses 2019 12 18 10.3390/v12010018 31877975 71. Nieto K Weghofer M Sehr P Ritter M Sedlmeier S Karanam B Seitz H Müller M Kellner M Hörer M Michaelis U Roden R B Gissmann L Kleinschmidt J A Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate PLoS One 2012 7 e39741 10.1371/journal.pone.0039741 22761884 72. Zhai L Peabody J Pang Y S Schiller J Chackerian B Tumban E A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9 Antiviral Res. 2017 147 116 123 10.1016/j.antiviral.2017.09.012 28939477 73. Woo E J Moro P L Cano M Jankosky C Postmarketing safety surveillance of trivalent recombinant influenza vaccine: reports to the vaccine adverse event reporting system Vaccine 2017 35 5618 5621 10.1016/j.vaccine.2017.08.047 28886946 74. Pushko P Tretyakova I Influenza virus like particles (VLPs): opportunities for H7N9 vaccine development Viruses 2020 12 518 10.3390/v12050518 32397182 75. Mallajosyula V V Citron M Ferrara F Temperton N J Liang X Flynn J A Varadarajan R Hemagglutinin sequence conservation guided stem immunogen design from influenza A H3 subtype Front. Immunol. 2015 6 329 10.3389/fimmu.2015.00329 26167164 76. Smith G E Sun X Bai Y Liu Y V Massare M J Pearce M B Belser J A Maines T R Creager H M Glenn G M Flyer D Pushko P Levine M Z Tumpey T M Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets Virology 2017 509 90 97 10.1016/j.virol.2017.06.006 28624679 77. Kingstad-Bakke B Kamlangdee A Osorio J E Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge Vaccine 2015 33 5155 5162 10.1016/j.vaccine.2015.08.005 26271828 78. Xie H Liu T M Lu X Wu Z Belser J A Katz J M Tumpey T M Ye Z A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice J. Infect. Dis. 2009 200 1874 1883 10.1086/648405 19909080 79. Schwartzman L M Cathcart A L Pujanauski L M Qi L Kash J C Taubenberger J K An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza A virus mBio 2015 6 e01044 10.1128/mBio.01044-15 26199334 80. Wiersma L C Rimmelzwaan G F de Vries R D Developing universal influenza vaccines: hitting the nail, not just on the head Vaccines (Basel) 2015 3 239 262 10.3390/vaccines3020239 26343187 81. Song J M Wang B Z Park K M Van Rooijen N Quan F S Kim M C Jin H T Pekosz A Compans R W Kang S M Influenza virus-like particles containing M2 induce broadly cross protective immunity PLoS One 2011 6 e14538 10.1371/journal.pone.0014538 21267073 82. Kim M C Lee J S Kwon Y M E O Lee Y J Choi J G Wang B Z Compans R W Kang S M Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection Antiviral Res. 2013 99 328 335 10.1016/j.antiviral.2013.06.010 23811283 83. Braz Gomes K D’Sa S Allotey-Babington G L Kang S M D’Souza M J Transdermal vaccination with the matrix-2 protein virus-like particle (M2e VLP) induces immunity in mice against influenza A virus Vaccines (Basel) 2021 9 1324 10.3390/vaccines9111324 34835255 84. Heinimäki S Lampinen V Tamminen K Hankaniemi M M Malm M Hytönen V P Blazevic V Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology Virology 2022 566 89 97 10.1016/j.virol.2021.12.001 34894525 85. Quan F S Kim M C Lee B J Song J M Compans R W Kang S M Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection Virology 2012 430 127 135 10.1016/j.virol.2012.05.006 22658901 86. Kim K H Lee Y T Park S Jung Y J Lee Y Ko E J Kim Y J Li X Kang S M Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus Virology 2019 535 179 188 10.1016/j.virol.2019.07.008 31310875 87. Menne Z Pliasas V C Compans R W Glover S Kyriakis C S Skountzou I Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model Virology 2021 562 197 208 10.1016/j.virol.2021.08.001 34375782 88. Yang J R Chen C Y Kuo C Y Cheng C Y Lee M S Cheng M C Yang Y C Wu C Y Wu H S Liu M T Hsiao P W A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses Antiviral Res. 2016 126 8 17 10.1016/j.antiviral.2015.10.019 26593980 89. Chen C W Saubi N Joseph-Munné J Design concepts of virus-like particle-based HIV-1 vaccines Front. Immunol. 2020 11 573157 10.3389/fimmu.2020.573157 33117367 90. Peters B S Cheingsong-Popov R Callow D Foxall R Patou G Hodgkin K Weber J N A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects J. Infect. 1997 35 231 235 10.1016/S0163-4453(97)92814-0 9459393 91. Veenstra J Williams I G Colebunders R Dorrell L Tchamouroff S E Patou G Lange J M Weller I V Goeman J Uthayakumar S Gow I R Weber J N Coutinho R A Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons J. Infect. Dis. 1996 174 862 866 10.1093/infdis/174.4.862 8843231 92. Rerks-Ngarm S Pitisuttithum P Nitayaphan S Kaewkungwal J Chiu J Paris R Premsri N Namwat C de Souza M Adams E Benenson M Gurunathan S Tartaglia J McNeil J G Francis D P Stablein D Birx D L Chunsuttiwat S Khamboonruang C Thongcharoen P Robb M L Michael N L Kunasol P Kim J H MOPH-TAVEG Investigators Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand N. Engl. J. Med. 2009 361 2209 2220 10.1056/NEJMoa0908492 19843557 93. Eto Y Saubi N Ferrer P Joseph-Munné J Expression of chimeric HPV-HIV protein L1P18 in Pichia pastoris ; purification and characterization of the virus-like particles Pharmaceutics 2021 13 1967 10.3390/pharmaceutics13111967 34834382 94. Zhang P Narayanan E Liu Q Tsybovsky Y Boswell K Ding S Hu Z Follmann D Lin Y Miao H Schmeisser H Rogers D Falcone S Elbashir S M Presnyak V Bahl K Prabhakaran M Chen X Sarfo E K Ambrozak D R Gautam R Martin M A Swerczek J Herbert R Weiss D Misamore J Ciaramella G Himansu S Stewart-Jones G McDermott A Koup R A Mascola J R Finzi A Carfi A Fauci A S Lusso P A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques Nat. Med. 2021 27 2234 2245 10.1038/s41591-021-01574-5 34887575 95. Liu D Zhang S Poteet E Marin-Muller C Chen C Yao Q Sublingual immunization with chimeric C1q/CD40 ligand/HIV virus-like particles induces strong mucosal immune responses against HIV Vaccines (Basel) 2021 9 1236 10.3390/vaccines9111236 34835167 96. Ao Z Wang L Azizi H Olukitibi T A Kobinger G Yao X Development and evaluation of an Ebola virus glycoprotein mucin-like domain replacement system as a new dendritic cell-targeting vaccine approach against HIV-1 J. Virol. 2021 95 e0236820 10.1128/JVI.02368-20 34011553 97. Chapman R van Diepen M Galant S Kruse E Margolin E Ximba P Hermanus T Moore P Douglass N Williamson A L Rybicki E Immunogenicity of HIV-1 vaccines expressing chimeric envelope glycoproteins on the surface of Pr55 Gag virus-like particles Vaccines (Basel) 2020 8 54 10.3390/vaccines8010054 32013223 98. Pillay S Shephard E G Meyers A E Williamson A L Rybicki E P HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice J. Immune Based Ther. Vaccines 2010 8 7 10.1186/1476-8518-8-7 21087527 99. Escolano A Gristick H B Gautam R DeLaitsch A T Abernathy M E Yang Z Wang H Hoffmann M A G Nishimura Y Wang Z Koranda N Kakutani L M Gao H Gnanapragasam P N P Raina H Gazumyan A Cipolla M Oliveira T Y Ramos V Irvine D J Silva M West A P Jr. Keeffe J R Barnes C O Seaman M S Nussenzweig M C Martin M A Bjorkman P J Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env Sci. Transl. Med. 2021 13 eabk1533 10.1126/scitranslmed.abk1533 34818054 100. Yu H Pardoll D Jove R STATs in cancer inflammation and immunity: a leading role for STAT3 Nat. Rev. Cancer 2009 9 798 809 10.1038/nrc2734 19851315 101. DeFazio-Eli L Strommen K Dao-Pick T Parry G Goodman L Winslow J Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action Breast Cancer Res. 2011 13 R44 10.1186/bcr2866 21496232 102. Sherwood J Mendelman P M Lloyd E Liu M Boslego J Borkowski A Jackson A Faix D US Navy study team Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults Vaccine 2020 38 6442 6449 10.1016/j.vaccine.2020.07.069 32878708 103. Pucci B Kasten M Giordano A Cell cycle and apoptosis Neoplasia 2000 2 291 299 10.1038/sj.neo.7900101 11005563 104. Bartek J Lukas J Pathways governing G1/S transition and their response to DNA damage FEBS Lett. 2001 490 117 122 10.1016/S0014-5793(01)02114-7 11223026 105. Han J C Li Q X Fang J B Zhang J Y Li Y Q Li S Z Cheng C Xie C Z Nan F L Zhang H Li Z X Jin N Y Zhu G Z Lu H J GII.P16-GII.2 recombinant norovirus VLPs polarize macrophages into the M1 phenotype for Th1 immune responses Front. Immunol. 2021 12 781718 10.3389/fimmu.2021.781718 34868056 106. Malm M Vesikari T Blazevic V Simultaneous immunization with multivalent norovirus VLPs induces better protective immune responses to norovirus than sequential immunization Viruses 2019 11 1018 10.3390/v11111018 31684058 107. Ward B J Gobeil P Séguin A Atkins J Boulay I Charbonneau P Y Couture M D’Aoust M A Dhaliwall J Finkle C Hager K Mahmood A Makarkov A Cheng M P Pillet S Schimke P St-Martin S Trépanier S Landry N Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19 Nat. Med. 2021 27 1071 1078 10.1038/s41591-021-01370-1 34007070 108. Fluckiger A C Ontsouka B Bozic J Diress A Ahmed T Berthoud T Tran A Duque D Liao M McCluskie M Diaz-Mitoma F Anderson D E Soare C An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity Vaccine 2021 39 4988 5001 10.1016/j.vaccine.2021.07.034 34304928 109. Fougeroux F Goksøyr C L Idorn M Soroka V Myeni S K Dagil R Janitzek C M Søgaard M Aves K L Horsted E W Erdogan S M Gustavsson T Dorosz J Clemmensen S Fredsgaard L Thrane S Vidal-Calvo E E Khalifé P Hulen T M Choudhary S Theisen M Singh S K Garcia-Senosiain A Van Oosten L Pijlman G Hierzberger B Domeyer T Nalewajek B W Strøbæk A Skrzypczak M Andersson L F Buus S Buus A S Christensen J P Dalebout T J Iversen K Harritshøj L H Mordmüller B Ullum H Reinert L S de Jongh W A Kikkert M Paludan S R Theander T G Nielsen M A Salanti A Sander A F Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity Nat. Commun. 2021 12 324 10.1038/s41467-020-20251-8 33436573 110. Dalvie, N. C., L. H. Tostanoski, S. A. Rodriguez-Aponte, K. Kaur, S. Bajoria, O. S. Kumru, A. J. Martinot, A. Chandrashekar, K. McMahan, N. B. Mercado, J. Yu, A. Chang, V. M. Giffin, F. Nampanya, S. Patel, L. Bowman, C. A. Naranjo, D. Yun, Z. Flinchbaugh, L. Pessaint, R. Brown, J. Velasco, E. Teow, A. Cook, H. Andersen, M. G. Lewis, D. L. Camp, J. M. Silverman, H. Kleanthous, S. B. Joshi, D. B. Volkin, S. Biswas, J. C. Love, and D. H. Barouch (2021) A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates. bioRxiv 10.1101/2021.07.13.452251 111. Royal J M Simpson C A McCormick A A Phillips A Hume S Morton J Shepherd J Oh Y Swope K DeBeauchamp J L Webby R J Cross R W Borisevich V Geisbert T W Demarco J K Bratcher B Haydon H Pogue G P Development of a SARS-CoV-2 vaccine candidate using plant-based manufacturing and a tobacco mosaic viruslike nano-particle Vaccines (Basel) 2021 9 1347 10.3390/vaccines9111347 34835278 112. Guo C Peng Y Lin L Pan X Fang M Zhao Y Bao K Li R Han J Chen J Song T Z Feng X L Zhou Y Zhao G Zhang L Zheng Y Zhu P Hang H Zhang L Hua Z Deng H Hou B A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates Cell Rep. Med. 2021 2 100448 10.1016/j.xcrm.2021.100448 34723223 113. van Oosten L Altenburg J J Fougeroux C Geertsema C van den End F Evers W A C Westphal A H Lindhoud S van den Berg W Swarts D C Deurhof L Suhrbier A Le T T Torres Morales S Myeni S K Kikkert M Sander A F de Jongh W A Dagil R Nielsen M A Salanti A Søgaard M Keijzer T M P Weijers D Eppink M H M Wijffels R H van Oers M M Martens D E Pijlman G P Two-component nanoparticle vaccine displaying glycosylated spike S1 domain induces neutralizing antibody response against SARS-CoV-2 variants mBio 2021 12 e0181321 10.1128/mBio.01813-21 34634927 114. Chang X Zeltins A Mohsen M O Gharailoo Z Zha L Liu X Walton S Vogel M Bachmann M F A novel double mosaic virus-like particle-based vaccine against SARS-CoV-2 incorporates both receptor binding motif (RBM) and fusion domain Vaccines (Basel) 2021 9 1287 10.3390/vaccines9111287 34835218 115. Chevillard C Amen A Besson S Hannani D Bally I Dettling V Gout E Moreau C J Buisson M Gallet S Fenel D Vassal-Stermann E Schoehn G Poignard P Dagher M C Fender P Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform Mol. Ther. 2022 30 1913 1925 10.1016/j.ymthe.2022.02.011 35151843 116. Ortega-Rivera O A Shin M D Chen A Beiss V Moreno-Gonzalez M A Lopez-Ramirez M A Reynoso M Wang H Hurst B L Wang J Pokorski J K Steinmetz N F Trivalent subunit vaccine candidates for COVID-19 and their delivery devices J. Am. Chem. Soc. 2021 143 14748 14765 10.1021/jacs.1c06600 34490778 117. Chen G L Coates E E Plummer S H Carter C A Berkowitz N Conan-Cibotti M Cox J H Beck A O’Callahan M Andrews C Gordon I J Larkin B Lampley R Kaltovich F Gall J Carlton K Mendy J Haney D May J Bray A Bailer R T Dowd K A Brockett B Gordon D Koup R A Schwartz R Mascola J R Graham B S Pierson T C Donastorg Y Rosario N Pape J W Hoen B Cabié A Diaz C Ledgerwood J E VRC 704 Study Team Effect of a Chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial JAMA 2020 323 1369 1377 10.1001/jama.2020.2477 32286643 118. Aslan Kosar P Tuncer H Cihangir Uğuz A Espino Palma J Darıcı H Onaran İ Çiğ B Koşar A Rodriguez Moratinos A B The efficiency of poly(ADP-Ribose) polymerase (PARP) cleavage on detection of apoptosis in an experimental model of testicular torsion Int. J. Exp. Pathol. 2015 96 294 300 10.1111/iep.12137 26303136 119. Loganathan R Selvaduray K R Nesaretnam K Radhakrishnan A K Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity Cell Prolif. 2013 46 203 213 10.1111/cpr.12014 23510475 120. Ku C R Lee H J Kim S K Lee E Y Lee M K Lee E J Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic β-cell and the cleavage of poly (ADP-ribose) polymerase Endocr. J. 2012 59 103 109 10.1507/endocrj.EJ11-0194 22068111 121. Park P # E J Shin J W Seo Y S Kim D W Hong S Y Park W I Kang B M Gonadotropin-releasing hormone-agonist induces apoptosis of human granulosa-luteal cells via caspase-8, -9 and -3, and poly-(ADP-ribose)-polymerase cleavage Biosci. Trends 2011 5 120 128 10.5582/bst.2011.v5.3.120 21788697 122. Pal H C Sehar I Bhushan S Gupta B D Saxena A K Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa Toxicol. In Vitro 2010 24 1599 1609 10.1016/j.tiv.2010.06.007 20600805 123. Mahfouz R Z Sharma R K Poenicke K Jha R Paasch U Grunewald S Agarwal A Evaluation of poly(ADP-ribose) polymerase cleavage (cPARP) in ejaculated human sperm fractions after induction of apoptosis Fertil. Steril. 2009 91 2210 2220 10.1016/j.fertnstert.2008.02.173 18501896 124. Zhang P Li H Chen D Ni J Kang Y Wang S Oleanolic acid induces apoptosis in human leukemia cells through caspase activation and poly(ADP-ribose) polymerase cleavage Acta Biochim. Biophys. Sin. (Shanghai) 2007 39 803 809 10.1111/j.1745-7270.2007.00335.x 17928930 125. Rodríguez-Hernández A Brea-Calvo G Fernández-Ayala D J Cordero M Navas P Sánchez-Alcázar J A Nuclear caspase-3 and caspase-7 activation, and poly(ADP-ribose) polymerase cleavage are early events in camptothecin-induced apoptosis Apoptosis 2006 11 131 139 10.1007/s10495-005-3276-y 16374543 126. Yinjun L Jie J Weilai X Xiangming T Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP) Am. J. Hematol. 2004 76 199 204 10.1002/ajh.20100 15224352",
  "plain_text": "Virus-like particles (VLPs) are viral structural protein that are noninfectious as they do not contain viral genetic materials. They are safe and effective immune stimulators and play important roles in vaccine development because of their intrinsic immunogenicity to induce cellular and humoral immune responses. In the design of antiviral vaccine, VLPs based vaccines are appealing multifunctional candidates with the advantages such as self-assembling nanoscaled structures, repetitive surface epitopes, ease of genetic and chemical modifications, versatility as antigen presenting platforms, intrinsic immunogenicity, higher safety profile in comparison with live-attenuated vaccines and inactivated vaccines. In this review, we discuss the mechanism of VLPs vaccine inducing cellular and humoral immune responses. We outline the impact of size, shape, surface charge, antigen presentation, genetic and chemical modification, and expression systems when constructing effective VLPs based vaccines. Recent applications of antiviral VLPs vaccines and their clinical trials are summarized."
}
